New combo therapy aims to shrink rectal tumors and avoid surgery

NCT ID NCT07527026

First seen Apr 16, 2026 · Last updated May 09, 2026 · Updated 5 times

Summary

This study tests whether adding the immunotherapy drug camrelizumab to standard chemoradiotherapy can help shrink tumors completely in people with locally advanced rectal cancer. About 44 adults aged 18-75 with a specific type of rectal cancer (pMMR/MSS) will receive a sequence of chemo-immunotherapy, radiation, and more chemo-immunotherapy before possible surgery. The goal is to see if this approach can increase the chance of a complete response and allow patients to keep their rectum.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.